<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The study of <z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e> has been primarily in Europids, despite the high prevalence of <z:mp ids='MP_0002055'>diabetes</z:mp> in other populations </plain></SENT>
<SENT sid="1" pm="."><plain>We set out to ascertain the prevalence of <z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e> and its risk factors in the island nation of Mauritius </plain></SENT>
<SENT sid="2" pm="."><plain>Population surveys were carried out in 1987 and 1992 in Mauritius to establish the prevalence of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In the second survey, vibration perception threshold (VPT) was also measured at the great toe in 847 subjects with <z:mp ids='MP_0002055'>diabetes</z:mp>, 204 subjects with <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> and 127 subjects with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e> was defined as levels of VPT exceeding the mean plus 2 standard deviations defined separately for three age groups of Mauritian non-diabetic subjects </plain></SENT>
<SENT sid="5" pm="."><plain>Risk factors for <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> were identified cross sectionally from the 1992 data, and longitudinally from the 1987 data </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">Neuropathy</z:e> was detected in 8.3% of the 847 diabetic subjects (12.7%) of those with known <z:mp ids='MP_0002055'>diabetes</z:mp>, and 3.6% of those with newly diagnosed <z:mp ids='MP_0002055'>diabetes</z:mp>) </plain></SENT>
<SENT sid="7" pm="."><plain>Logistic regression identified <z:mp ids='MP_0002055'>diabetes</z:mp> duration (odds ratio [95% CI]; 1.08 [1.04-1.13] per year, P=0.0002), treatment with insulin or oral hypoglycaemic agents (2.63 [1.36-5.09], P=0.004) and greater height (1.36 [1.19-1.57] per 5 cm, P &lt; 0.001) as risk factors for <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, in the cross sectional analysis </plain></SENT>
<SENT sid="8" pm="."><plain>In the longitudinal analysis, <z:mp ids='MP_0002055'>diabetes</z:mp> duration (1.11 [1.05-1.18] per year, P=0.001), fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> (1.12 [1.03-1.22] per mmol/l, P=0.01) and height (1.23 [1.03-1.45] per 5 cm, P=0.02) were associated with <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>A lower 2-h plasma insulin was also associated with <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> in the longitudinal analysis </plain></SENT>
<SENT sid="10" pm="."><plain>The prevalence of <z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e> in Mauritius is the lowest reported for any population, but the risk factors associated with it are similar to those previously found </plain></SENT>
</text></document>